GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Qiagen NV (NYSE:QGEN) » Definitions » Price-to-Owner-Earnings

Qiagen NV (Qiagen NV) Price-to-Owner-Earnings

: 50.60 (As of Today)
View and export this data going back to 1996. Start your Free Trial

As of today (2024-04-19), Qiagen NV's share price is $39.47. Qiagen NV's Owner Earnings per Share (TTM) ended in Dec. 2023 was $0.78. It's Price-to-Owner-Earnings for today is 50.60.


The historical rank and industry rank for Qiagen NV's Price-to-Owner-Earnings or its related term are showing as below:

QGEN' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 19.16   Med: 48.66   Max: 200.83
Current: 50.34

During the past 13 years, the highest Price-to-Owner-Earnings of Qiagen NV was 200.83. The lowest was 19.16. And the median was 48.66.


QGEN's Price-to-Owner-Earnings is ranked worse than
79.1% of 67 companies
in the Medical Diagnostics & Research industry
Industry Median: 24.4 vs QGEN: 50.34

As of today (2024-04-19), Qiagen NV's share price is $39.47. Qiagen NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $1.53. Therefore, Qiagen NV's PE Ratio for today is 25.87.

As of today (2024-04-19), Qiagen NV's share price is $39.47. Qiagen NV's EPS without NRI for the trailing twelve months (TTM) ended in was $2.00. Therefore, Qiagen NV's PE Ratio without NRI for today is 19.70.

During the past 13 years, Qiagen NV's highest PE Ratio without NRI was 49.71. The lowest was 15.56. And the median was 27.70.


Qiagen NV Price-to-Owner-Earnings Historical Data

The historical data trend for Qiagen NV's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qiagen NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 38.02 31.50 28.85 57.11

Qiagen NV Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.85 38.53 49.81 68.56 57.11

Competitive Comparison

For the Diagnostics & Research subindustry, Qiagen NV's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Qiagen NV Price-to-Owner-Earnings Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Qiagen NV's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Qiagen NV's Price-to-Owner-Earnings falls into.



Qiagen NV Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Qiagen NV's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=39.47/0.78
=50.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Qiagen NV  (NYSE:QGEN) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Qiagen NV Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Qiagen NV's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Qiagen NV (Qiagen NV) Business Description

Address
Hulsterweg 82, Venlo, LI, NLD, 5912 PL
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (over 45% of 2022 sales), followed by EMEA (nearly 35%), and Asia-Pacific (nearly 20%).
Executives
Prof. Dr. Elaine R. Mardis Supervisory Board
Roland Sackers Board of Directors
Thierry Bernard Board of Directors
Lawrence A. Rosen Supervisory Board